Won Yong Kim

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Jacob Lønborg
  • ,
  • Niels Grove Vejlstrup
  • ,
  • Henning Skov Kelbæk
  • ,
  • Hans Erik Bøtker
  • Won Yong Kim
  • Anders B Mathiasen, Denmark
  • Erik Jørgensen, Department of Cardiology, Rigshospitalet, Denmark
  • Steffen Helqvist
  • ,
  • Peter Clemmensen
  • ,
  • Kari Saunamäki
  • ,
  • Lene Holmvang
  • ,
  • Leif Thuesen, Denmark
  • Lars Romer Krusell, Denmark
  • Jan S Jensen, Denmark
  • Lars Køber
  • ,
  • Marek Treiman
  • ,
  • Jens Juul Holst
  • ,
  • Thomas Engstrøm
AimsExenatide, a glucagon-like-peptide-1 analogue, increases myocardial salvage in experimental settings with coronary occlusion and subsequent reperfusion. We evaluated the cardioprotective effect of exenatide at the time of reperfusion in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI).Methods and resultsA total of 172 patients with STEMI and Thrombolysis in Myocardial Infarction flow 0/1 were randomly assigned to exenatide or placebo (saline) intravenously. Study treatment was commenced 15 min before intervention and maintained for 6 h after the procedure. The primary endpoint was salvage index calculated from myocardial area at risk (AAR), measured in the acute phase, and final infarct size measured 90 ± 21 days after pPCI by cardiac magnetic resonance (CMR). In 105 patients evaluated with CMR, a significantly larger salvage index was found in the exenatide group than in the placebo group (0.71 ± 0.13 vs. 0.62 ± 0.16; P= 0.003). Infarct size in relation to AAR was also smaller in the exenatide group (0.30 ± 0.15 vs. 0.39 ± 0.15; P= 0.003). In a regression analysis, there was a significant correlation between the infarct size and the AAR for both treatment groups and an analysis of covariance showed that datapoints in the exenatide group lay significantly lower than for the placebo group (P= 0.011). There was a trend towards smaller absolute infarct size in the exenatide group (13 ± 9 vs. 17 ± 14 g; P= 0.11). No difference was observed in left ventricular function or 30-day clinical events. No adverse effects of exenatide were observed.ConclusionIn patients with STEMI undergoing pPCI, administration of exenatide at the time of reperfusion increases myocardial salvage.
Original languageEnglish
JournalEuropean Heart Journal
Volume33
Issue12
Pages (from-to)1491-1499
Number of pages9
ISSN0195-668X
DOIs
Publication statusPublished - Jun 2012

See relations at Aarhus University Citationformats

ID: 40482033